

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA - Atezolizumab for adjuvant treatment of resected non-
small-cell lung cancer [ID6324]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No equality issues raised by stakeholders

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?
N/A

3. Has any change to the draft scope been agreed to highlight potential equality issues?
N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
N/A

Approved by Associate Director (name): Lorna Dunning

Date: 26 September 24